Parkman Healthcare Partners LLC Has $2.25 Million Stock Position in InspireMD, Inc. (NYSE:NSPR)

Parkman Healthcare Partners LLC increased its position in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) by 721.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 854,716 shares of the company's stock after purchasing an additional 750,635 shares during the period. Parkman Healthcare Partners LLC owned approximately 3.28% of InspireMD worth $2,248,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in NSPR. Schonfeld Strategic Advisors LLC raised its stake in shares of InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after acquiring an additional 18,233 shares during the period. Northern Trust Corp increased its position in shares of InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after purchasing an additional 24,452 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of InspireMD in the 4th quarter valued at about $27,000. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD in the 4th quarter valued at about $191,000. Finally, Legato Capital Management LLC acquired a new position in shares of InspireMD in the 4th quarter valued at about $47,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Stock Performance

Shares of NYSE:NSPR traded down $0.03 during trading on Monday, reaching $2.34. The company had a trading volume of 22,469 shares, compared to its average volume of 37,380. InspireMD, Inc. has a twelve month low of $2.07 and a twelve month high of $3.80. The firm has a market capitalization of $71.53 million, a PE ratio of -3.11 and a beta of 0.62. The firm's fifty day moving average is $2.62 and its 200 day moving average is $2.74.

Wall Street Analyst Weigh In

NSPR has been the subject of a number of analyst reports. StockNews.com started coverage on shares of InspireMD in a research note on Monday, May 5th. They set a "sell" rating for the company. Piper Sandler reduced their price target on shares of InspireMD from $4.50 to $4.00 and set an "overweight" rating for the company in a research note on Monday, May 12th.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.